Biotech Startups

Reflector provides a machine learning platform that predicts functional responses of small molecules across diverse cellular contexts to prioritize drug candidates earlier in the discovery process. The tool helps pharmaceutical teams assess phenotypic effects, identify off-target liabilities, and classify mechanisms of action before committing to expensive downstream experiments.

1 investor

Refoxy is a science-driven company focused on drug discovery, medicinal chemistry, and bioinformatics. The team page emphasizes deep science and collaboration, but the page provides only placeholder text about the company's specific work.

1 investor

Regatta Bio develops precision regulatory T-cell (Treg) therapies aimed at inducing immune tolerance for patients with immune-driven conditions such as chronic graft-versus-host disease, transplant rejection, autoimmune diseases, and inflammatory conditions. The company positions its approach as an alternative to broad immunosuppression across cell transplants, organ transplants, and autoimmunity.

1 investor

Regenosca develops TissueSpan, an absorbable mesh implant that prompts the body to attract and organize its own cells for soft tissue regeneration, reinforcing or replacing damaged tissue. Its initial target application is urethral stricture repair, with potential use across a range of regenerative surgical interventions.

1 investor

Regentis Biomaterials develops regenerative medicine products for tissue repair, focused on orthopedic cartilage and bone treatments through its Gelrin degradable hydrogel platform. Its lead product, GelrinC, is a cell-free hydrogel implant for repairing articular knee cartilage injuries, CE-marked in Europe and in US clinical trials toward PMA approval.</parameter> <parameter name="founders">[]

1 investor

Reglagene develops a brain-penetrant oral drug therapy designed to treat primary tumors and brain metastases in patients with cancer. The company focuses on CNS oncology, targeting a mechanism validated in solid tumors but previously unexploited for brain-penetrant therapies.

1 investor

1 investor

REKAH Pharmaceutical Industries is an Israeli manufacturer of generic pharmaceuticals, cosmetics, vitamins, nutritional supplements, and medical devices, with subsidiaries handling production, R&D, marketing, sales, distribution, and international expansion.

1 investor

BEAUTE DE LABO develops and supplies beauty treatment products and services for women, with a focus on skincare and professional training. The company operates training centers across Japan and sells products through a network of licensed beauty salons and advisors.

1 investor

Relevium Medical is a biopharmaceutical company developing long-lasting treatments for chronic pain conditions, particularly osteoarthritis. The company focuses on therapeutic hydrogels and drug discovery for patients with debilitating pain.

1 investor

Reliant AI builds applied AI software for the life sciences industry, using machine learning and reinforcement learning to automate literature reviews, systematic reviews, competitive landscaping, and data extraction from full-text papers and conference documents. It serves biopharma teams including commercial, medical, and consulting groups, and offers knowledge graphs and secure, privacy-preserving workspaces.

1 investor

RELISTOR is a prescription medication containing methylnaltrexone bromide that treats opioid-induced constipation in adults with chronic pain or advanced illness. The drug is available in tablet and injection forms and is marketed for patients requiring pain management with opioids.

1 investor

1 investor

Remedium Bio is a biotech company developing gene therapy and biologic treatments for osteoarthritis and other rheumatology and metabolic conditions, drawing on research into cartilage regeneration and the FGF18 protein. Its work targets diseases such as osteoarthritis, arthritis, and diabetes-related metabolic conditions.

1 investor

Ren BioScience develops small-molecule therapies aimed at preserving organ function, including an oral lead compound for inherited retinal diseases and preclinical programs targeting acute kidney injury and mitochondrial-driven metabolic and autoimmune conditions. Its focus is on protecting cells from irreversible injury across ophthalmic, renal, and metabolic disease areas.

1 investor

ReNerve develops nerve repair products, including cuffs, grafts, and bionic nerve structures, to treat transected nerves and improve patient outcomes. The company operates research laboratories in Melbourne, Australia, and collaborates with researchers at the CSIRO / Monash University biomaterials precinct.

1 investor

Renova Therapeutics develops investigational gene therapies intended as single-dose, long-lasting treatments for common chronic diseases, with an initial focus on congestive heart failure and type 2 diabetes. The company builds a platform of therapeutics and delivery systems based on proprietary insights into disease mechanisms.

1 investor

Renovion develops ARINA-1, a next-generation mucolytic therapy delivered as a sterile buffered ascorbic acid and glutathione solution to the lungs. The therapy targets chronic inflammatory airway diseases affecting over 170 million patients globally, including non-cystic fibrosis bronchiectasis, chronic bronchitis, COPD, and asthma.

1 investor

RenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.

1 investor

Renovo Solutions operates a Life Sciences business line providing services and solutions to pharmaceutical, biotech, medical device, and laboratory services companies.

1 investor

RenovoDerm is a life sciences company developing wound care and tissue technology platforms within the medtech and biotech sectors. It operates as a commercial subsidiary of Paragen Technologies.

1 investor

REOME sells high-performance skincare products, including serums, creams, and eye treatments powered by biotechnology and bio-active ingredients such as DHK-3. It offers a direct-to-consumer collection of clinically-focused products aimed at hydrating, smoothing, and firming skin.

1 investor

Reprogram Biosciences develops an in vivo immunotherapy that uses a therapeutic gene cocktail delivered via lipid nanoparticles to reprogram solid-tumor cancer cells into immune-like cells. The company operates in the biotech and cancer therapeutics field, applying gene reprogramming and AI-driven bioinformatics to develop cell therapies for solid tumors.

1 investor

REPROSENT captures patient treatment experience data to support dose, safety, and development decisions in oncology and advanced cancer therapies. The platform operates as a lightweight, non-interventional overlay on existing clinical trials and care programs, converting patient symptoms into structured, computable signal for development and clinical teams.

1 investor